Verve Therapeutics, INC Form 4 insider transactions
Jason Politi, Chief Technical Operations Officer at Verve Therapeutics, received stock options and restricted stock units as part of his compensation.
Form 4: Verve Therapeutics Chief Scientific Officer Granted Stock Options and Restricted Stock Units
Troy Lister, Chief Scientific Officer of Verve Therapeutics, was granted stock options and restricted stock units on January 8, 2025, according to a recent SEC filing.
Verve Therapeutics CEO, Sekar Kathiresan, received stock options and restricted stock units on January 8, 2025, as part of his compensation.
Joan Nickerson, Chief Administrative Officer of Verve Therapeutics, was granted stock options and restricted stock units on January 8, 2025.
Andrew D. Ashe, President, COO, and General Counsel of Verve Therapeutics, was granted stock options and restricted stock units on January 8, 2025.
Verve Therapeutics CEO, Sekar Kathiresan, transferred 30,000 shares of company stock to a family trust on December 4, 2024.
Verve Therapeutics' Chief Financial Officer, Allison Dorval, recently executed transactions involving the company's stock, including the vesting of restricted stock units and a subsequent sale to cover tax obligations.
Form 4: Verve Therapeutics CEO Sekar Kathiresan Reports Stock Option Exercise and Share Transactions
CEO Sekar Kathiresan reports exercising stock options and acquiring shares of Verve Therapeutics, Inc.
Director Krishna Yeshwant acquired stock options in Verve Therapeutics, Inc. on June 26, 2024, under the company's 2021 Stock Incentive Plan.
Director Sheila Mikhail reports the acquisition of stock options in Verve Therapeutics, Inc.
Director Burt A. Adelman reports the grant of stock options in Verve Therapeutics, Inc.
Alexander Cumbo, a director at Verve Therapeutics, acquired stock options for 136,139 shares of common stock on June 26, 2024.
Director Ourania Tatsis reports the acquisition of stock options in Verve Therapeutics, Inc.
Jodie Pope Morrison, a director at Verve Therapeutics, was granted stock options for 267,541 shares on June 26, 2024, according to a Form 4 filing.
Director Lonnel Coats acquired stock options in Verve Therapeutics, Inc. on June 26, 2024, under the company's 2021 Stock Incentive Plan.
Director Michael MacLean acquired stock options in Verve Therapeutics, Inc. on June 26, 2024, as part of the company's director compensation program.
Troy Lister, Chief Scientific Officer of Verve Therapeutics, reports the acquisition of stock options in the company.
Andrew Ashe, President and COO of Verve Therapeutics, reports purchasing 76,000 shares of VERV common stock at an average price of $6.26.
Joan Nickerson, Chief Administrative Officer of Verve Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.